Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.2K
Tumor Progression02:07

Tumor Progression

7.4K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.7K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

428
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
428
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

156
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
156
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

256
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
256

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Decline and mortality of poplar shelterbelt induced by hydraulic limitations, carbon starvation, and drying of mid-depth soil layers.

Ying yong sheng tai xue bao = The journal of applied ecology·2026
Same author

Red-yellow Papules and Nodules All over the Body: A Quiz.

Acta dermato-venereologica·2026
Same author

Phenotype-dependent effects of IL-17A inhibitors on lipid profiles in moderate-to-severe plaque psoriasis: a retrospective cohort study.

Lipids in health and disease·2026
Same author

The role of disease-modifying anti-rheumatic drugs (DMARDs) in cardiovascular risk management induced by rheumatoid arthritis.

Experimental cell research·2026
Same author

Tumor necrosis factor inhibitors enhance corticosteroid therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis linked to immune checkpoint inhibitors: a prospective study.

Frontiers in immunology·2024
Same author

Stevens-Johnson syndrome and toxic epidermal necrolysis associated with immune checkpoint inhibitors: a systematic review.

Frontiers in immunology·2024

Related Experiment Video

Updated: Jan 27, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.5K

Research Progress on PARP14 as a Drug Target.

Wei Qin1, Hong-Jie Wu1, Lu-Qi Cao1

  • 1Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Shaanxi Key Laboratory of Brain disorders, Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, China.

Frontiers in Pharmacology
|March 21, 2019
PubMed
Summary

Poly-adenosine diphosphate-ribose polymerase 14 (PARP14) is a promising drug target for cancers and allergic inflammation due to its role in DNA repair and immune signaling. Inhibitors may offer new therapeutic strategies, but potential adverse effects require careful consideration.

Keywords:
PARP14allergic inflammationatherosclerosiscancerdrug targetmolecular mechanism

More Related Videos

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes
11:31

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes

Published on: February 18, 2020

8.3K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Related Experiment Videos

Last Updated: Jan 27, 2026

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
08:34

A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening

Published on: October 16, 2015

10.5K
Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes
11:31

Targeting Drugs to Larval Zebrafish Macrophages by Injecting Drug-Loaded Liposomes

Published on: February 18, 2020

8.3K
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

14.7K

Area of Science:

  • Biochemistry and Molecular Biology
  • Cancer Biology
  • Immunology

Background:

  • Poly-adenosine diphosphate-ribose polymerase (PARP) enzymes regulate crucial cellular processes through ADP-ribosylation.
  • PARP14 (ARTD8/BAL2) is emerging as a significant target, distinct from extensively studied PARP1/2.

Purpose of the Study:

  • To review the molecular mechanisms of PARP14 as a drug target for various cancers and allergic inflammatory diseases.
  • To explore PARP14's potential as a chemosensitizer in cancer therapy via synthetic lethality and DNA repair pathways.

Main Methods:

  • Literature review of current research on PARP family members, focusing on PARP14.
  • Analysis of molecular mechanisms underlying PARP14's role in cancer and inflammation.
  • Discussion of potential therapeutic applications and associated adverse effects of PARP inhibitors.

Main Results:

  • PARP14 utilizes NAD+ for mono-ADP-ribosylation, impacting immune system signaling and cellular responses.
  • PARP14 is implicated in the pathogenesis of diffuse large B-cell lymphoma, multiple myeloma, prostate cancer, and hepatocellular carcinoma.
  • PARP14's involvement in homologous recombination DNA repair suggests its utility as a chemosensitizer.

Conclusions:

  • PARP14 represents a promising therapeutic target for treating cancers and allergic inflammatory conditions.
  • Further research into PARP14 inhibitors could lead to novel drug discovery and chemosensitizer development.
  • Understanding PARP14's mechanisms is crucial for optimizing cancer and inflammation therapies while managing potential side effects.